Comparing the 2025 ESC/EAS Focused Update and the 2026 ACC/AHA Dyslipidemia Guideline: Convergences, Divergences, and Practical Implications

To compare the 2025 ESC/EAS Focused Update and the 2026 ACC/AHA Dyslipidemia Guideline, with emphasis on convergences, divergences, and their practical implications for lipid management.

Narrative comparative review of the two original guideline documents, organized around risk estimation, treatment goals, biomarkers, coronary artery calcium, non-statin therapy, secondary prevention, and clinical implementation.

The two documents share a common direction of travel: earlier recognition of risk, broader use of non-statin therapies, and more sustained lowering of atherogenic burden. The ESC/EAS update preserves a target-based framework and emphasizes faster intensification, especially after acute coronary syndromes (ACS). The ACC/AHA guideline broadens the field from cholesterol management to dyslipidemia, gives greater operational weight to apoB, non-HDL-C, and coronary artery calcium (CAC), and embeds treatment decisions within a more differentiated phenotypic framework.

The documents often support similar therapeutic decisions, but they differ in how risk is refined, how residual atherogenic burden is interpreted, and how treatment is intensified. The ESC/EAS text places greater emphasis on earlier treatment intensification within an established framework, whereas the ACC/AHA guideline provides a broader and more differentiated management framework.